Oligonucleotide Synthesis Industry - Overview
Advancing technologies have substantially raised the hope for better treatment in the healthcare sector. One of the chief driving forces is biotechnology which is constantly updating itself and impacting the former sector. Of the many ensuing projects, oligonucleotide synthesis is an evolving technique that forms inexpensive, custom-made oligonucleotides with the desired sequence. Its importance lies in its contribution in DNA or RNA synthesizing and hybridization and in the synthesis of artificial genes.
The global Oligonucleotide Synthesis Industry is expecting an astonishing 10.3% CAGR during the forecast period (2014-2022), reveals Market Research Future (MRFR) in a broadly demonstrated report. The report further incorporates factors that are contributing much for the market growth which includes ventures and investments made by big pharmaceutical companies, contract manufacturing organization’s involvement in the market and global prevalence of chronic diseases spurring the demand for better medicines.
However, the cost can prove to be a great market deterrent. The oligonucleotide synthesis requires expert hands, and its research and development process can incur high expenditure which can impede the growth in the near future. But it has the potential to counter chronic diseases by developing suitable drugs which can create a favorable ambiance for the market.
OligonucleotideSynthesis Industry Segmentation:
The global Oligonucleotide Synthesis Industry can be segmented by product type, application, and end-users.
Based on product type, the market can be segmented into synthesized oligonucleotides, reagents and equipment.
Application-wise segmentation of the market includes diagnostic, genetic testing, research, therapeutics, gene synthesis, library preparation, drug target screening, and others.
Based on end-users, the market comprises academic research institutes, diagnostic laboratories, and pharmaceutical & biotechnology companies.
Oligonucleotide Synthesis Industry Competitive Dashboard:
The competitive market is witnessing several strategies being implemented by market behemoths. For instance, Danaher’s taking over of Integrated DNA Technologies can be seen as an effort to enhance the market portfolio. LGC is following the same suit by acquiring BioAutomation Corporation, the latter a manufacturer of the renowned MerMade oligo synthesis instruments. On the other hand, STA Pharmaceuticals has signed a collaboration with Regulus to establish high-quality oligonucleotide research and development center.
Some of the key players in this market are Integrated DNA Technologies, Inc (U.S), GE Healthcare (U.S.), Agilent Technologies Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Bioautomation Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), L.G.C Biosearch Technologies (U.S.), Eurofins Genomics (Germany), Eurogentec S.A (Belgium), and Nitto Denko Avecia Inc. (Japan) and others.
Comments
Post a Comment